Skip to main content

Advertisement

SpringerLink
Log in

Recent Advances Toward the Clinical Application of PTH (1-34) in Fracture Healing

  •  
  • Published:
HSS Journal

Abstract

PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Madore GR, Sherman PJ, Lane JM (2004) Parathyroid hormone. J Am Acad Orthop Surg 12:67–71

    PubMed  Google Scholar 

  2. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  PubMed  CAS  Google Scholar 

  3. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  4. Alkhiary YM, Gerstenfeld LC, Krall E et al (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731–741

    Article  PubMed  Google Scholar 

  5. Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960–968

    Article  PubMed  CAS  Google Scholar 

  6. Andreassen TT, Fledelius C, Ejersted C et al (2001) Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 72:304–307

    Article  PubMed  CAS  Google Scholar 

  7. Andreassen TT, Willick GE, Morley P et al (2004) Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 74:351–356

    Article  PubMed  CAS  Google Scholar 

  8. Holzer G, Majeska RJ, Lundy MW et al (1999) Parathyroid hormone enhances fracture healing. A preliminary report. Clin Orthop Relat Res 366:258–263

    Article  PubMed  Google Scholar 

  9. Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 23:1089–1094

    PubMed  CAS  Google Scholar 

  10. Komatsubara S, Mori S, Mashiba T et al (2005) Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36:678–687

    Article  PubMed  CAS  Google Scholar 

  11. Nakajima A, Shimoji N, Shiomi K et al (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038–2047

    Article  PubMed  CAS  Google Scholar 

  12. Nakazawa T, Nakajima A, Shiomi K et al (2005) Effects of low-dose, intermittent treatment with recombinant human parathyroid hormone (1-34) on chondrogenesis in a model of experimental fracture healing. Bone 37:711–719

    Article  PubMed  CAS  Google Scholar 

  13. Kronenberg HM (2006) PTHrP and skeletal development. Ann N Y Acad Sci 1068:1–13

    Article  PubMed  CAS  Google Scholar 

  14. Martin TJ, Quinn JM, Gillespie MT et al (2006) Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 1068:458–470

    Article  PubMed  CAS  Google Scholar 

  15. Everhart-Caye M, Inzucchi SE, Guinness-Henry J et al (1996) Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. J Clin Endocrinol Metab 81:199–208

    Article  PubMed  CAS  Google Scholar 

  16. Hock JM, Fonseca J, Gunness-Hey M et al (1989) Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022–2027

    Article  PubMed  CAS  Google Scholar 

  17. Weir EC, Terwilliger G, Sartori L et al (1992) Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo. Calcif Tissue Int 51:30–34

    Article  PubMed  CAS  Google Scholar 

  18. Okazaki K, Jingushi S, Ikenoue T et al (2003) Expression of parathyroid hormone-related peptide and insulin-like growth factor I during rat fracture healing. J Orthop Res 21:511–520

    Article  PubMed  CAS  Google Scholar 

  19. Chung UI, Lanske B, Lee K et al (1998) The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci U S A 95:13030–13035

    Article  PubMed  CAS  Google Scholar 

  20. Kobayashi T, Chung UI, Schipani E et al (2002) PTHrP and Indian hedgehog control differentiation of growth plate chondrocytes at multiple steps. Development 129:2977–2986

    PubMed  CAS  Google Scholar 

  21. Lanske B, Karaplis AC, Lee K et al (1996) PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663–666

    Article  PubMed  CAS  Google Scholar 

  22. Vortkamp A, Lee K, Lanske B et al (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273:613–622

    Article  PubMed  CAS  Google Scholar 

  23. Dempster DW, Cosman F, Kurland ES et al (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853

    Article  PubMed  CAS  Google Scholar 

  24. Lindsay R, Zhou H, Cosman F et al (2007) Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495–502

    Article  PubMed  CAS  Google Scholar 

  25. Misof BM, Roschger P, Cosman F et al (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156

    Article  PubMed  CAS  Google Scholar 

  26. Bostrom MP, Gamradt SC, Asnis P et al (2000) Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 26:437–442

    Article  PubMed  CAS  Google Scholar 

  27. Miller PD, Schwartz EN, Chen P et al (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59–68

    Article  PubMed  CAS  Google Scholar 

  28. Miller PD, Bilezikian JP, Diaz-Curiel M et al (2007) Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 92(9):3535–3541

    Article  PubMed  CAS  Google Scholar 

  29. Medication Guide. Indianapolis I Eli Lilly and Company 2002

  30. Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321

    Article  PubMed  CAS  Google Scholar 

  31. Vahle JL, Zuehlke U, Schmidt A et al (2008) Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 18:9–17

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orthopaedic Trauma Service, Hospital for Special Surgery, 535 East 70th Street, New York, NY, 10021, USA

    Paul S. Issack MD, PhD, Clément M. L. Werner MD & David L. Helfet MD

  2. Orthopaedic Trauma and Adult Reconstructive Surgery, Hospital for Special Surgery, New York, NY, USA

    Paul S. Issack MD, PhD

  3. University of Pennsylvania School of Medicine, Philadelphia, PA, USA

    Cara A. Cipriano BA

  4. Metabolic Bone Disease Service, Hospital for Special Surgery, New York, NY, USA

    Lisa Shindle MSN, NP & Joseph M. Lane MD

  5. Weill-Cornell Medical Center, New York, NY, USA

    David L. Helfet MD

Authors
  1. Cara A. Cipriano BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul S. Issack MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Shindle MSN, NP
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Clément M. L. Werner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David L. Helfet MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph M. Lane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul S. Issack MD, PhD.

Additional information

One or more of the authors (JML) has received funding from (Eli Lilly)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cipriano, C.A., Issack, P.S., Shindle, L. et al. Recent Advances Toward the Clinical Application of PTH (1-34) in Fracture Healing. HSS Jrnl 5, 149–153 (2009). https://doi.org/10.1007/s11420-009-9109-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11420-009-9109-8

Keywords

Search

Navigation